Univariable analysis for risk factors predicting fatal and nonfatal thrombotic events in the follow-up of 707 patients with PMF
| . | HR . | 95% CI . | P . |
|---|---|---|---|
| Sex, males vs females | 0.96 | 0.54-1.71 | .90 |
| Age older than 60 y | 2.45 | 1.33-4.58 | .004 |
| Previous thrombosis | 1.75 | 0.74-4.11 | .20 |
| Splenomegaly | |||
| No | 1 (ref) | ||
| 5 cm or less | 0.91 | 0.37-2.22 | .84 |
| 5-10 cm | 0.76 | 0.30-1.93 | .57 |
| 11-15 cm | 0.51 | 0.14-1.77 | .29 |
| More than 15 cm | 0.47 | 0.10-2.25 | .39 |
| Dupriez score | |||
| Low | 1 (ref) | ||
| Intermediate-high | 1.67 | 1.01-2.75 | .045 |
| IPSS | |||
| Low-intermediate1 | 1 (ref) | ||
| Intermediate 2-high | 1.84 | 0.97-3.50 | .06 |
| Cardiovascular risk factors* | 2.25 | 0.90-5.61 | .08 |
| Hb level, g/L | |||
| Less than 110 | 1 (ref) | ||
| 110 or higher | 0.91 | 0.51-1.63 | .75 |
| PLT count, ×109/L† | |||
| Less than 450 | 1 (ref) | ||
| 450 or higher | 0.98 | 0.54-1.77 | .94 |
| WBC count, ×109/L‡ | |||
| Less than 15 | 1 (ref) | ||
| 15 or higher | 2.00 | 1.10-3.66 | .02 |
| JAK2 V617F | 3.86 | 1.37-9.47 | .009 |
| Cytoreductive therapy | 1.46 | 0.78-2.75 | .24 |
| Splenectomy | 0.86 | 0.41-1.78 | .68 |
| . | HR . | 95% CI . | P . |
|---|---|---|---|
| Sex, males vs females | 0.96 | 0.54-1.71 | .90 |
| Age older than 60 y | 2.45 | 1.33-4.58 | .004 |
| Previous thrombosis | 1.75 | 0.74-4.11 | .20 |
| Splenomegaly | |||
| No | 1 (ref) | ||
| 5 cm or less | 0.91 | 0.37-2.22 | .84 |
| 5-10 cm | 0.76 | 0.30-1.93 | .57 |
| 11-15 cm | 0.51 | 0.14-1.77 | .29 |
| More than 15 cm | 0.47 | 0.10-2.25 | .39 |
| Dupriez score | |||
| Low | 1 (ref) | ||
| Intermediate-high | 1.67 | 1.01-2.75 | .045 |
| IPSS | |||
| Low-intermediate1 | 1 (ref) | ||
| Intermediate 2-high | 1.84 | 0.97-3.50 | .06 |
| Cardiovascular risk factors* | 2.25 | 0.90-5.61 | .08 |
| Hb level, g/L | |||
| Less than 110 | 1 (ref) | ||
| 110 or higher | 0.91 | 0.51-1.63 | .75 |
| PLT count, ×109/L† | |||
| Less than 450 | 1 (ref) | ||
| 450 or higher | 0.98 | 0.54-1.77 | .94 |
| WBC count, ×109/L‡ | |||
| Less than 15 | 1 (ref) | ||
| 15 or higher | 2.00 | 1.10-3.66 | .02 |
| JAK2 V617F | 3.86 | 1.37-9.47 | .009 |
| Cytoreductive therapy | 1.46 | 0.78-2.75 | .24 |
| Splenectomy | 0.86 | 0.41-1.78 | .68 |
Values in bold are statistically significant (P < .05).
PMF indicates primary myelofibrosis; HR, hazard ratio; IPSS, International Prognostic Scoring System; Hb, hemoglobin; PLT, platelet; WBC, white blood cell; and ref, reference.
Smoking, arterial hypertension, and diabetes (at least 1).
With the cutoff of 750 × 109/L: HR = 0.44, P = .56.
Best cutoff derived by receiver operating characteristic analysis.